Effect of unani medicine in vomiting in pregnancy

Efficacy of Sikanjabeen Lemooni in Qayal Haml.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/03/012345

Enrollment

Registered

2018-03-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Nausea and vomiting in pregnancy

Interventions

Intervention1: Sikanjabeen Lemooni: Sikanjabeen lemooni 25 ml two times before meals for 14 days Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Pregnant woman with nausea and vomiting Singleton intrauterine pregnancy Gestational age range 7 to 14 weeks

Exclusion criteria

Exclusion criteria: Hyperemesis gravidarum and women treated by other antiemetics and patient with any medical conditions associated with pregnancy like severe anemia and hypertension and diabetes melllitus and women with history of other non obstetrical causes of vomiting like appendicitis and cholecystitis

Design outcomes

Primary

Measure	Time frame
Change in nausea and vomiting in pregnancyTimepoint: Two weeks	—

Secondary

Measure	Time frame
Change in PUQE (Pregnancy Unique Quantification of Emesis) and NVPQOL (Nausea and vomiting in pregnancy-specific Quality of life questionnaire) Timepoint: Two weeks	—

Countries

India

Contacts

Public ContactDr Kouser Fathima Firdose

National institute of unani medicine

kouser2fathima@gmail.com9141762284

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026